Revvity Signs Agreement to Acquire Human Cell Design
As wet-lab validation becomes increasingly important to support artificial intelligence-enhanced science, research science points out that human-relevant cell models provide an important foundation for testing and confirming AI-generated insights. The post Revvity Signs Agreement to Acquire Human Cell Design appeared first on GEN - Genetic Engineering and Biotechnology News .
Revvity has reached an agreement to acquire Human Cell Design (HCD), a French biotechnology company focused on human cell models and preclinical research for metabolic diseases such as diabetes and obesity. The acquisition, targeting Q4 2026, will enhance Revvity's Life Sciences portfolio with HCD's specialized human pancreatic beta cell models, which are crucial for drug discovery, screening, and preclinical research.
Prahlad Singh, Revvity's president and CEO, highlighted how HCD's models complement Revvity's existing technologies, offering integrated solutions to customers. HCD's flagship EndoC-βH5 model, designed to mimic human beta cell physiology, will be invaluable in diabetes and obesity research. Additionally, HCD provides unique media, reagents, and a NatLine cell-line development platform that can broaden Revvity's global customer base.
This strategic move aligns with Revvity's commitment to developing high-quality, human-relevant cell models and supporting the AI-driven era in scientific research.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
